Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of PF-07275315 in Healthy Participants
NCT05411588Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) and asthma comparing PF-07275315 with Placebo (2 arms). Primary endpoints: Number of participants with Adverse Events (AEs), Number of participants with clinically meaningful change from baseline in laboratory Tests Results and 3 more. Started Jun 2022; status: completed.
02
Drugs
tilrekimig
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on NCT05411588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411588.